Dianthus Therapeutics, Inc. DNTH 深 沪
等待开盘 10-07 09:30:00 美东时间
83.69
-4.350
-4.94%
华盛通- 最 高113.86
- 今 开88.58
- 成交量 40.98万股
- 最 低 83.57
- 昨 收 88.04
- 总市值 0
- 52周最高 117.875
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 32.28
- 委 比 -81.82%
- 总股本 --
- 历史最高 117.875
- 量 比 0.97
- 振 幅 34.40%
- 历史最低 0.321
- 每 手 1
- 风险率 26.93%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position: Analyst
Sanofi discontinues Phase 3 riliprubart study for CIDP due to low efficacy. SNY stock ticks up. Read the market & analyst reaction.
06-11 21:09
This CrowdStrike Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Wall Street analysts upgraded CRWD, ALEC, RIVN, SEDG, and DNTH. See what other analysts say about these stocks. Consider buying CRWD.
03-10 20:32
Dianthus Therapeutics Announces Proposed $400M Public Offering
Dianthus announced that it has commenced an underwritten public offering of $400 million of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase
03-10 04:03
Dianthus Therapeutics Stock Rallies—Rare Disease Study Success Fuels Optimism
Dianthus Therapeutics shares jump after early success in a Phase 3 trial for CIDP treatment claseprubart, signaling potential progress toward approval.
03-09 21:22
Dianthus Therapeutics Earnings Review: Q4 Summary
Dianthus Therapeutics (NASDAQ:DNTH) announced its Q4 earnings on Monday, March ...
03-09 19:36
【晨观方正】创新药多个BD落地映证产业趋势持续 / 香港楼市是怎样止跌回稳的？20251021
今天是2025年10月21日星期二，农历八月二十九。每一个秋日的清晨，方正研究向您提供及时新鲜的研究观点，秉持“独立、客观、理性、真诚”的理念，珍重您的信任，保...
2025-10-21 08:33
一天三个BD，创新药再掀狂潮！翰森制药逆市涨近4%，BD总额超15.3亿美元！港股通创新药ETF(159570)资金近20日净流入超29亿元！
今日（10.17），在连续两日反攻后，港股通创新药ETF（159570）回调一度超1%，现跌幅收窄至0.38%，盘中成交额快速突破8.6亿元！资金面上，近20日...
2025-10-17 11:18
10亿美元出海，来自今年最火IPO之一
（来源：动脉新医药） 10月16日晚，南京维立志博与Dianthus Therapeutics宣布已就DNTH212（LBL-047）达成独家许可协议。双方达成...
2025-10-17 08:00
维立志博-B(09887)就LBL-047与DIANTHUS签订全球独家许可协议
维立志博-B(09887)发布公告，于2025年10月16日，本公司与Dianthus Therapeutics, Inc.(Dianthus，纳斯达克代码：...
2025-10-16 20:55
Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference
Dianthus Therapeutics announced its participation in the Jefferies Global Healthcare Conference, with CEO Marino Garcia to hold a fireside chat and investor meetings. The company focuses on developing advanced antibody therapies for severe autoimmune diseases.
2025-05-29 11:00
